Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Pharmacogenomics J. 2011 Aug 16;13(1):35–43. doi: 10.1038/tpj.2011.38

Figure 2. Population class distribution of the top meta-analysis hits.

Figure 2

The number of SNPs with a meta p-value < 10−4 that have a MAF > 0.05 in each population panel included in the listed population classes. Most (50.3% for carboplatin and 45.5% for cisplatin) of the top SNPs (p < 10−4) were present in all 7 panels. For the vast majority of these SNPs present in all 7 panels, the direction of effect was the same for either 7/7 or 6/7 panels (98.1% for carboplatin, 96.7% for cisplatin). SNPs not included in this bar chart were present in a subset of panels not included as one of the listed population classes.